pgo_tte: Probability to go to phase III for multiarm programs with...

In Sterniii3/drugdevelopR: Utility-Based Optimal Phase II/III Drug Development Planning

Probability to go to phase III for multiarm programs with time-to-event outcomes

Description

Given our parameters this function calculates the probability to go to phase III after the second phase was conducted. The considered strategies are as follows:

• 1. Strategy: Only best promising treatment goes to phase III

Usage

pgo_tte(HRgo, n2, ec, hr1, hr2, strategy, case)

Arguments

HRgo	threshold value for the go/no-go decision rule
n2	total sample size in phase II, must be divisible by 3
ec	control arm event rate for phase II and III
hr1	assumed true treatment effect on HR scale for treatment 1
hr2	assumed true treatment effect on HR scale for treatment 2
strategy	choose Strategy: 1 ("only best promising"), 2 ("all promising")
case	different cases: 1 ("nogo"), 21 (treatment 1 is promising, treatment 2 is not), 22 (treatment 2 is promising, treatment 1 is not), 31 (both treatments are promising, treatment 1 is better), 32 (both treatments are promising, treatment 2 is better)

Value

The function pgo_tte() returns the probability to go to phase III.

Examples

res <- pgo_tte(HRgo = 0.8, n2 = 48 , ec = 0.6, hr1 = 0.7, hr2 = 0.8, strategy = 2, case = 31)

Sterniii3/drugdevelopR documentation built on Jan. 14, 2025, 7:50 p.m.